Securities Class Action Lawsuit Filed Against Alto Neuroscience, Inc.

Investors in Alto Neuroscience, Inc. may be affected by a class action securities lawsuit alleging securities fraud. The lawsuit claims that the company's initial public offering in February 2024 and subsequent stock sales between February 2024 and October 2024 were misleading, as the company allegedly overstated the effectiveness of its product pipeline, ALTO-100. The case is ongoing, and investors have until September 19, 2025, to request appointment as lead plaintiff. Joseph E. Levi, Esq. and Ed Korsinsky, Esq. of Levi & Korsinsky, LLP are representing the plaintiffs.

Key Takeaways:

• The class action lawsuit alleges that Alto Neuroscience, Inc. made false statements and/or concealed the effectiveness of its product pipeline, ALTO-100.
• The lawsuit claims that the company's business and/or financial prospects were overstated due to the allegedly misleading clinical, regulatory, and commercial prospects of ALTO-100.
• The plaintiffs must request appointment as lead plaintiff by September 19, 2025, to participate in the lawsuit.
• Levi & Korsinsky, LLP, a securities litigation firm with over 20 years of experience, is representing the plaintiffs.
• The firm has secured hundreds of millions of dollars for aggrieved shareholders and has a track record of winning high-stakes cases.
• Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States for seven consecutive years.

Statistics:

• The lawsuit covers securities purchases between February 2, 2024, and October 22, 2024.
• The plaintiffs must have purchased or otherwise acquired Alto common stock or securities during this time period to be eligible to participate in the lawsuit.
• The filing deadline for the lawsuit is September 19, 2025.